Search the Newsreel

Abbott Laboratories (NYSE:ABT) Receives Consensus Rating of "Moderate Buy" from Brokerages

Abbott Laboratories (NYSE:ABT) has received a consensus "Moderate Buy" rating from twenty-six brokerages, with an average 12-month price target of $118.17. The company recently exceeded quarterly expectations with adjusted EPS of $1.31 and revenue of $12.59 billion, and announced a quarterly dividend of $0.63 …

BERKLEY W R CORP Exits AMC Robotics Corp (AMCI) Position in Sold Out Transaction

BERKLEY W R CORP has fully divested its stake in AMC Robotics Corp (AMCI) as of June 30, 2026, selling all shares at $4.98 each. This exit aligns with BERKLEY W R CORP's value-oriented investment strategy, which favors stable, income-generating assets over speculative growth, …

Is It Too Late To Consider Buying Shanghai MicroPort MedBot (Group) Co., Ltd. (HKG:2252)?

¿Puede Abbott Laboratories (ABT) Estar 8% Infravalorada Tras Mejorar Su Previsión Anual?

PRCT Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against PROCEPT BioRobotics Corporation and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit

Robbins Geller Rudman & Dowd LLP has filed a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors who purchased stock between February 28, 2024, and February 25, 2026. The lawsuit alleges that PROCEPT made materially false and misleading statements …

PROCEPT BioRobotics (PRCT) Q2 2026 Earnings Call Transcript

Cabot CEO Sean Keohane sells $7.9m in stock

Cabot Corp CEO Sean Keohane sold common stock worth approximately $7.9 million on August 7, 2026, after exercising employee stock options. He acquired 91,923 shares at $62.24 each and then sold them at a weighted average price of $86.4053. Following these transactions, Keohane directly …

Ibotta (IBTA) holders register 16,491-share NYSE sale via J.P. Morgan

Ibotta Class A shareholders have filed to sell up to 16,491 shares of Class A Common Stock on the NYSE through J.P. Morgan Securities LLC, with an aggregate market value of $596,809. The filing also details past sales in May 2026 by Thomas D. …

Ibotta (IBTA) insiders file Form 144 for $925K stock sale

Ibotta, Inc. insiders have filed a Form 144, indicating their intent to sell 25,571 shares of Class A Common Stock with an aggregate market value of $925,415. The proposed sale is scheduled for August 11, 2026, through J.P. Morgan Securities LLC on the NYSE. …

Arbe Robotics Expands AI Radar Push as It Targets Defense, Drones and Robotaxis

Arbe Robotics is expanding the application of its ultra-high-resolution radar technology beyond the automotive sector to target defense, security, drones, and marine markets. The company, which produces radar semiconductor chipsets, is now manufacturing complete radar units for non-automotive uses due to slower-than-expected automotive adoption …

Abbott Laboratories (ABT) schedules NYSE sale of stock from vested awards

Abbott Laboratories (ABT) has filed a Form 144 indicating a planned sale of 5,850 common shares through UBS Financial Services on or after August 11, 2026, on the NYSE. The shares originate from vested restricted stock awards granted on February 27, 2026, totaling 1,960, …

GMEX Robotics Accelerates AI Robotics Platform Strategy With MediaMeta.Ai Deal and 247meta.ai Launch Plan

Uber Blindsides Serve Robotics With Surprise Stake Sale

Uber has unexpectedly sold its entire stake in Serve Robotics without prior notice to the company, signaling a significant strategic divergence in their approach to autonomous delivery. This move reflects Uber's shift towards larger autonomous vehicles and robotaxis, moving away from sidewalk delivery robots. …

PROCEPT CLASS ACTION ALERT: Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. has filed a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors who purchased common stock between February 28, 2024, and February 25, 2026. The lawsuit alleges that Procept misled investors by failing to disclose …

Ibotta (IBTA) CTO Swanson sells 800 shares, retains 483,764 in direct stake

Ibotta's CTO, Luke Roy Swanson, sold 800 shares of Class A Common Stock on August 7, 2026, under a Rule 10b5-1 trading plan. The sales included 200 direct shares and 600 indirect shares, with prices ranging from $39.90 to $39.91 per share. After these …

ARBE: Radar commercialization accelerates, targeting breakeven by 2028 and major deployments by 2029

Arbe Robotics (ARBE) is accelerating the commercialization of its ultra-high-resolution radar technology, which is used in automotive, defense, and civilian sectors. The company is targeting revenue growth, with a goal to achieve breakeven by 2028. Major deployments are anticipated in China and the U.S. …

Uber surprised robotics company Serve by selling its entire stake

Uber has divested its entire stake in Serve Robotics, an autonomous delivery robot company that originated from Uber's acquisition of Postmates. This move came as a surprise to Serve Robotics, which learned of the selloff through a regulatory filing. The divestiture follows differing views …

Ubtech Robotics (SEHK:9880) Is Getting Fresh Attention, What Is The Market Watching?

Microbot Medical Inc. Q2 2026: Revenue $241K, Net loss $5.63M — 10-Q Summary

Microbot Medical Inc. reported its Q2 2026 results, announcing its first commercial revenue of $241,000, a significant increase from zero in the previous year. Despite this, the company posted a net loss of $5.63 million, worsening from a $3.5 million loss in the prior-year …

Microbot Medical Q2 Results: Sales miss by 29%, EPS in line

Microbot Medical (NASDAQ: MBOT) reported Q2 EPS of $(0.08), meeting analyst estimates and showing a 20% improvement year-over-year. However, the company's sales of $241,000 significantly missed the estimated $340,000 by 29.12%, raising concerns about its top-line growth despite improved per-share losses. This discrepancy suggests …

Abbott Partners With Google Health For AI-Powered Glucose Monitoring

Abbott has partnered with Google Health to integrate its Lingo continuous glucose monitor (CGM) data into the Google Health app, offering AI-driven recommendations for non-diabetic users. This collaboration aims to help users make better lifestyle choices and will involve a large-scale metabolic health study. …

Abbott to integrate Google’s AI health coach into wearable glucose monitoring tech

Abbott is partnering with Google to integrate Google's AI health coach into its Lingo wearable glucose monitoring technology. This collaboration aims to enhance the functionality of Abbott's continuous glucose monitoring system by providing users with AI-powered personalized health insights and coaching. The initiative was …

Kaplan Fox Encourages Investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to Contact the Firm to Learn About Their Legal Rights

Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors who purchased common stock between February 28, 2024, and February 25, 2026. The lawsuit alleges that PROCEPT artificially inflated its reported U.S. handpiece …

UBTECH Robotics Calls 2026 Extraordinary Meeting to Approve Financing and H-Share Incentive Plan

Microbot Medical (NASDAQ:MBOT) Issues Earnings Results

Microbot Medical (NASDAQ:MBOT) announced its earnings results, reporting a quarterly loss of $0.08 per share, which met analyst expectations, but revenue of $0.24 million fell short of the $0.33 million consensus. Following the announcement, shares declined 13.4% to $1.68, nearing the company's one-year low. …

Microbot Medical partners with Lovell Government Services to target federal healthcare systems

Microbot Medical has partnered with Lovell Government Services to expand its reach into federal healthcare systems, gaining access to over 2,000 facilities for its LIBERTY endovascular robotic system. Concurrently, Microbot signed an agreement with Sanmina to establish a second manufacturing site, anticipating increased demand. …

Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates

Microbot Medical Inc. (MBOT) reported a Q2 loss of $0.08 per share, in line with the Zacks Consensus Estimate, but missed revenue expectations with $0.24 million against an anticipated $0.31 million. Despite underperforming the market year-to-date, the company holds a Zacks Rank #2 (Buy), …

Lost Money on PROCEPT BioRobotics Corporation (PRCT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm

The Gross Law Firm has issued a notice to shareholders of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to join a class action lawsuit. The suit alleges that PROCEPT BioRobotics Corporation made false or misleading statements regarding an undisclosed discount program that inflated sales and revenue, …

Por que as ações da Abbott Laboratories estão subindo hoje? - Investing.com Brasil

Why is Abbott Laboratories stock gaining today?

Abbott Laboratories stock rose 1.2% after announcing a multi-year collaboration with Google Health. This partnership will integrate glucose data from Abbott's Lingo biowearable continuous glucose monitor into the Google Health app, offering personalized health recommendations. The deal also includes a large-scale metabolic health study, …

Microbot Medical (NASDAQ: MBOT) posts first LIBERTY sales with $67M in cash

Microbot Medical (NASDAQ: MBOT) has reported its first commercial revenue from the LIBERTY® Endovascular Robotic System, totaling $241,000 in Q2 2026 and $346,000 for the first half of 2026. Despite these initial sales, the company incurred a net loss of $5.6 million for the …

Microbot Medical's LIBERTY System Gets Marketing Clearance in Israel

Microbot Medical (NASDAQ: MBOT) reported over 100% revenue and customer growth in Q2 2026, driven by the successful Full Market Release of its LIBERTY endovascular robotic system. The company expanded its U.S. sales territories, partnered for access to federal healthcare facilities, and received marketing …

Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI

Abbott and Google Health have announced a multi-year partnership to integrate glucose insights from Abbott's Lingo biowearable with Google's AI and consumer technology. This collaboration aims to provide personalized metabolic insights through the Google Health app, helping users understand how daily behaviors affect their …

Abbott, Google to Study How Sleep and Activity Affect Glucose

Abbott has announced a multi-year partnership with Google Health to integrate insights from Abbott's Lingo continuous glucose monitor with Google's AI and consumer technology. This collaboration aims to provide personalized metabolic insights through the Google Health app, offering AI-powered guidance on nutrition, activity, sleep, …

GMEX Robotics Unveils Mount Cutting Robot Sensor Downtime by Up to 90%

Embotelladora Andina S.A. (ANDINA-A.SN) Analyst Insights, Price Targets & Recommendations

This Yahoo Finance page provides a snapshot of Embotelladora Andina S.A. (ANDINA-A.SN), including its current stock price, recent performance, and dividend announcement. The company's stock closed at 3,683.70 CLP, down 0.33%, and has declared a cash dividend of CLP 51.00 with an ex-date of …